These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35900161)

  • 1. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders.
    Bandelow B; Allgulander C; Baldwin DS; Costa DLDC; Denys D; Dilbaz N; Domschke K; Eriksson E; Fineberg NA; Hättenschwiler J; Hollander E; Kaiya H; Karavaeva T; Kasper S; Katzman M; Kim YK; Inoue T; Lim L; Masdrakis V; Menchón JM; Miguel EC; Möller HJ; Nardi AE; Pallanti S; Perna G; Rujescu D; Starcevic V; Stein DJ; Tsai SJ; Van Ameringen M; Vasileva A; Wang Z; Zohar J
    World J Biol Psychiatry; 2023 Feb; 24(2):79-117. PubMed ID: 35900161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD.
    Bandelow B; Allgulander C; Baldwin DS; Costa DLDC; Denys D; Dilbaz N; Domschke K; Hollander E; Kasper S; Möller HJ; Eriksson E; Fineberg NA; Hättenschwiler J; Kaiya H; Karavaeva T; Katzman MA; Kim YK; Inoue T; Lim L; Masdrakis V; Menchón JM; Miguel EC; Nardi AE; Pallanti S; Perna G; Rujescu D; Starcevic V; Stein DJ; Tsai SJ; Van Ameringen M; Vasileva A; Wang Z; Zohar J
    World J Biol Psychiatry; 2023 Feb; 24(2):118-134. PubMed ID: 35900217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.
    Bandelow B; Zohar J; Hollander E; Kasper S; Möller HJ; ; Zohar J; Hollander E; Kasper S; Möller HJ; Bandelow B; Allgulander C; Ayuso-Gutierrez J; Baldwin DS; Buenvicius R; Cassano G; Fineberg N; Gabriels L; Hindmarch I; Kaiya H; Klein DF; Lader M; Lecrubier Y; Lépine JP; Liebowitz MR; Lopez-Ibor JJ; Marazziti D; Miguel EC; Oh KS; Preter M; Rupprecht R; Sato M; Starcevic V; Stein DJ; van Ameringen M; Vega J
    World J Biol Psychiatry; 2008; 9(4):248-312. PubMed ID: 18949648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
    Bandelow B; Sher L; Bunevicius R; Hollander E; Kasper S; Zohar J; Möller HJ; ;
    Int J Psychiatry Clin Pract; 2012 Jun; 16(2):77-84. PubMed ID: 22540422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders.
    Bandelow B; Zohar J; Hollander E; Kasper S; Möller HJ;
    World J Biol Psychiatry; 2002 Oct; 3(4):171-99. PubMed ID: 12516310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.
    Baldwin DS; Anderson IM; Nutt DJ; Allgulander C; Bandelow B; den Boer JA; Christmas DM; Davies S; Fineberg N; Lidbetter N; Malizia A; McCrone P; Nabarro D; O'Neill C; Scott J; van der Wee N; Wittchen HU
    J Psychopharmacol; 2014 May; 28(5):403-39. PubMed ID: 24713617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Novel Psychopharmacological Drugs for Anxiety Disorders.
    Bandelow B
    Adv Exp Med Biol; 2020; 1191():347-365. PubMed ID: 32002937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis.
    Motta LS; Gosmann NP; Costa MA; Jaeger MB; Frozi J; Grevet LT; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum G
    BMJ Ment Health; 2023 Feb; 26(1):. PubMed ID: 37142305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The German Guidelines for the treatment of anxiety disorders: first revision.
    Bandelow B; Werner AM; Kopp I; Rudolf S; Wiltink J; Beutel ME
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):571-582. PubMed ID: 34609587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
    Sarris J; Ravindran A; Yatham LN; Marx W; Rucklidge JJ; McIntyre RS; Akhondzadeh S; Benedetti F; Caneo C; Cramer H; Cribb L; de Manincor M; Dean O; Deslandes AC; Freeman MP; Gangadhar B; Harvey BH; Kasper S; Lake J; Lopresti A; Lu L; Metri NJ; Mischoulon D; Ng CH; Nishi D; Rahimi R; Seedat S; Sinclair J; Su KP; Zhang ZJ; Berk M
    World J Biol Psychiatry; 2022 Jul; 23(6):424-455. PubMed ID: 35311615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines.
    Buszewicz M; Cape J; Serfaty M; Shafran R; Kabir T; Tyrer P; Clarke CS; Nazareth I
    Health Technol Assess; 2017 Aug; 21(45):1-138. PubMed ID: 28853392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults.
    Skapinakis P; Caldwell D; Hollingworth W; Bryden P; Fineberg N; Salkovskis P; Welton N; Baxter H; Kessler D; Churchill R; Lewis G
    Health Technol Assess; 2016 Jun; 20(43):1-392. PubMed ID: 27306503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
    Marazziti D; Carlini M; Dell'Osso L
    Curr Top Med Chem; 2012; 12(4):238-53. PubMed ID: 22204483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.
    de Vries YA; Roest AM; Burgerhof JGM; de Jonge P
    Depress Anxiety; 2018 Jun; 35(6):515-522. PubMed ID: 29659102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
    Zohar J; Westenberg HG
    Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions.
    Bauer M; Whybrow PC; Angst J; Versiani M; Möller HJ;
    World J Biol Psychiatry; 2002 Apr; 3(2):69-86. PubMed ID: 12479080
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.